Arkolith/Insider Trading/IDYA/Form 4

Hata Yujiro S

President and CEO, DirectorIDEAYA Biosciences, Inc. (IDYA) · full profile →Form 4 · filed May 16, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7.4M
Net Open-Market Flow
-$7.4M
Transactions
13
10 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 16, 2024Sell(S)4K$42.37$184K678K
May 16, 2024Sell(S)30K$41.73$1.3M682K
May 16, 2024Option exercise(M)34K$4.31$148K712K
May 15, 2024Sell(S)503$44.12$22K678K
May 15, 2024Sell(S)54K$42.57$2.3M708K
May 15, 2024Sell(S)30K$43.48$1.3M678K
May 15, 2024Option exercise(M)84K$4.31$361K762K
May 14, 2024Sell(S)54K$41.60$2.3M680K
May 14, 2024Option exercise(M)57K$4.31$244K735K
May 14, 2024Sell(S)2K$41.84$96K678K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 16, 2024Option exercise(M)34K—$049K
May 15, 2024Option exercise(M)84K—$084K
May 14, 2024Option exercise(M)57K—$0168K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-24-000239) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML